Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Deutsche Beteiligungs to acquire Romaco Group
Romaco develops customer solutions for various forms of drug packaging and delivery systems and complex processing applications. DBAG Board of Management member Rolf Scheffell said in partnering with
Romaco develops customer solutions for various forms of drug packaging and delivery systems and complex processing applications. DBAG Board of Management member Rolf Scheffell said in partnering with
Currently, Lanxess is supplying specialty chemicals, color pigments to the Middle East customers for the construction industry and high-tech plastics and rubbers. The company has named Elie Saad
Besides, a product portfolio of over 100 research-based ELISA kits that cover research categories such as angiogenesis, apoptosis, endocrinology, immunology, inflammation, oncology and signal transduction will also be
The ABSORB trial is a prospective, non-randomized (open label), two-phase study that recruited 131 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key
Dymista (also known as MP29-02 in clinical trials), is a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis. Efficacy and safety of Dymista
As per the terms of the agreement, Eisai is expected to get exclusive worldwide rights (excluding some countries) for the development and commercialization o f compound as well
The study is expected to show a clinically meaningful and significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects. The
As per the agreement, Invida will leverage its capabilities for the management of all of the marketing and sales activities for Roche‘s primary care products, including Xenical, and
The increase of approximately $796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due
The company has received the US Food and Drug Administration approval for Axiron on 23 November 2010. Eli Lilly said the study results demonstrated that Axiron helped in